He is the head of HHS, and yet he continues to spout untested, unproven therapies and has only given a very lukewarm ...

U.S. Food and Drug Administration Commissioner Martin Makary announced on Thursday a policy to limit employees of companies ...

The stock's rise snapped a three-day losing streak.

Drugmaker Novartis plans to spend $23 billion at 10 of its U.S. facilities, as the pharma industry grapples with Trump’s ...

President Donald Trump has ordered the Department of Health and Human Services to standardize Medicare payments in an effort ...

U.S. tariffs on pharmaceuticals could eventually mean higher prices for brand-name medicines, but in the near term the costs ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

The Dow Jones Industrial Average (DJIA) declined on Thursday despite many stocks on the index rising. Instead, a few major ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the ...

Merck signs deal with Austria's Cyprumed to develop oral peptide therapies, potentially paying up to $493 million for access ...

We recently published a list of 10 Value Stocks in Ken Fisher’s Portfolio. In this article, we are going to take a look at ...

Companies and investors are grappling with a tariff landscape poised to keep shifting as the Trump administration negotiates ...